AbSci
  • Our Technology
  • Partnerships
  • About Us
  • Careers
  • News / Updates
  • Contact
  • Facebook
  • Twitter
  • Linkedin
Select Page
Sanofi turns to high titer E. Coli platform in AbSci deal

Sanofi turns to high titer E. Coli platform in AbSci deal

Jan 16, 2019 | News, Press

“Next-generation antibodies and proteins scaffolds present a roughly $14bn market opportunity by 2024 and getting to clinic six to 15 months sooner is a huge advantage, and a key driver, for partnering with AbSci.”

AbSci Establishes New Collaboration with Sanofi  

AbSci Establishes New Collaboration with Sanofi  

Jan 9, 2019 | Announcement, News, Press

“This collaboration illustrates the need for new expression technologies that are capable of producing these next-generation antibody and protein scaffolds. We’ve shown SoluProTM can uniquely deliver on this industry need.”

Recent Posts

  • AbSci Announces Acquisition of Deep Learning Company Denovium
  • AbSci to Present at the 39th Annual J.P. Morgan Healthcare Conference
  • AbSci Announces Recent Additions to Board of Directors
  • AbSci Announces $65 Million Financing Led by Casdin Capital
  • Alpha Cancer Technologies to License AbSci’s SoluPro Strain for the Expression of Alpha-Fetoprotein

Archives

  • January 2021
  • November 2020
  • October 2020
  • September 2020
  • January 2020
  • July 2019
  • March 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • July 2018
  • May 2018
  • February 2018
  • January 2018
  • December 2017
  • October 2017
  • August 2017
  • April 2017
  • January 2017
  • October 2016
  • August 2016
  • May 2016
  • April 2016
  • October 2015
SEE ARCHIVE

Categories

  • Announcement
  • Article
  • Award
  • Fundraising
  • News
  • Press
  • Uncategorized

Designed by Elegant Themes | Powered by WordPress